(2013) 126:S142
We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )
Store boxed Lipo Lab at least 10 cm (4 inches) from the back wall to avoid condensation points and ensure adequate air circulation
List of Key and Emerging Players in GLP-1 Supplement Market Nestl Health Science (Switzerland) Abbott (US) Danone (France) Herbalife (US) Thorne (US) NOW Foods (US) Garden of Life (US) OLLY (US) Supergut (US) Bioniq (UK) Viome (US) Persona Nutrition (US) Liquid I.V
&srotate=0)
